Global Gestational Trophoblastic Disease Market

Posted by shankar on December 19th, 2020

Global Gestational Trophoblastic Disease Market size was valued US$ XX Mn. in 2019 and the total revenue is expected to grow at 4.10% through 2019 to 2027, reaching nearly US$ XX Mn.

The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Gestational trophoblastic disease (GTD) is a spectrum of diseases that affect women mostly of reproductive age. Gestational trophoblastic disease entities are derived from placental origin, ranging from abnormal products of conception with malignant potential to malignant gestational trophoblastic neoplasia (GTN).

The report analyzes various factors which have been driving the global trophoblastic disease market in the past. Also, the MMR report analyzes the impact of each driver and restraint on the market growth, which forms the base for market forecast. The report also showcases the opportunities available in the trophoblastic disease market which may act as future drivers for the market. Such as, upsurge in risk factors affecting this spectrum of disease is expected to fuel the growth of the market. These risk factors contain the rise in ectopic pregnancies, high maternal age, and excessive smoking.

As per the American Lung Association, cigarette smoking kills an expected 201,770 women annually in the U.S. Also, the growing innovations in the field of oncology in expected contributing significantly to the growth in GTD market globally. Such as, in 2018 Bristol-Myers Squibb Company announced a clinical collaboration to evaluate therapeutic regimen in advanced solid tumors. On the Other hand, high risk of repetition of the tumors, even after multi or single-agent chemotherapy and difficulty in diagnosing the types of hydatidiform moles may hinder the GTD market growth.

The report covers the segments in the gestational trophoblastic disease market such as type, treatment, and end user. By type, the hydatidiform mole segment is expected to continue to hold the largest XX.17% share in the gestational trophoblastic disease market because of most common form of the gestational trophoblastic disease.
North America gestational trophoblastic disease market was valued at US$ XX.02 Mn. in 2019 and is expected to reach a value of US$ XX.19 Mn. by 2027, with a CAGR of XX.53% during the forecast period. This is because of an increased awareness about the disease and favorable reimbursement scenario. Also, the upsurge in many marketing approvals, as well as product approvals in the field of oncology drives the GTD market growth. On the other hand, the MEA has the least share of the gestational trophoblastic disease market due to the lack of technical expertise and stringent government regulations in the treatment of the disease.

In recent years, major companies in the gestational trophoblastic disease market have taken various strategic measures, like facility expansions and partnerships. Such as, in 2018, Novartis AG Company entered into a license and collaboration agreement with Cellular Biomedicine Group, a clinical stage biopharmaceutical company which improves therapies for cancer and degenerative diseases in China.

The objective of the report is to present a comprehensive analysis of the Global Gestational Trophoblastic Disease Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Gestational Trophoblastic Disease Market dynamics, structure by analyzing the market segments and projects the Global Gestational Trophoblastic Disease Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Gestational Trophoblastic Disease Market make the report investor’s guide.
Scope of the Global Gestational Trophoblastic Disease Market

Global Gestational Trophoblastic Disease Market, by Type

• Hydatidiform mole
o Complete
o Partial
o Invasive
• Choriocarcinoma
• Placental-site trophoblastic tumor
• Epithelioid trophoblastic tumor
• Others
Global Gestational Trophoblastic Disease Market, by Treatment

• Surgery
o Abdominal hysterectomy
o Vaginal hysterectomy
• Chemotherapy
• Suction dilation and curettage (D&C)
• Radiation Therapy
Global Gestational Trophoblastic Disease Market, by End user

• Hospital and clinics
• Diagnostic centers
• Others
Global Gestational Trophoblastic Disease Market, by Region

• Asia Pacific
• North America
• Europe
• South America
• Middle East & Africa
Key players operating in the Global Gestational Trophoblastic Disease Market

• Hikma Pharmaceuticals PLC
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Antares Pharma
• Mylan N.V.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• BP Pharmaceuticals Laboratories Company
• Fresenius Kabi AG
• Accord Healthcare, Inc.
• Eli Lilly and Company
• Sanofi
• Bayer AG
• Amgen Inc.
• Merck